Eli Lilly and Company
NYSEEli Lilly and Company reported Q2 earnings on August 5, and the defensive positioning that defined the prior three weeks of coverage has begun to dissolve — the question now is whether the stock's 8.6% weekly decline represents a post-print reset or the start of a deeper re-rating. The most striking shift from the pre-earnings setup is in options. The put/call ratio has retreated to…
LLY short interest climbs 21% in one week to 1.19% of float, driven by short sellers rebuilding positions as stock digests recent pipeline gains.
A new long-form analysis for LLY this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumEli Lilly and Company reported Q2 earnings on August 5, and the defensive positioning that defined the prior three weeks of coverage has begun to dissolve — the question now is whether the stock's 8.6% weekly decline…
Snapshot as of 5 Aug 2026
Eli Lilly and Company arrives at Wednesday's Q2 release with the stock having retreated from its all-time high, options hedging re-intensifying to the highest level of the past year, and short sellers holding their…
Eli Lilly and Company enters its August 5 Q2 print having added another 3.8% on the week to $1,220.66 — clearing the previous all-time high and leaving the defensive surge flagged two days ago looking slightly less…
Eli Lilly and Company has fallen a further 6.7% this week to $1,152.54, yet the analyst community has responded by raising targets — a widening gap between Street conviction and market price that defines this week's…
Eli Lilly and Company enters the back half of the week at $1,235.56, up 3% on the week, with a chorus of freshly raised analyst targets and an August 5 earnings date pulling focus. The Street's conviction is running…
Eli Lilly and Company closed the week at $1,199, pulling back 2.5% on Tuesday after touching record highs — the question now is whether that single-day fade is profit-taking or something more cautious ahead of the…
Eli Lilly and Company has found its footing after two weeks of selling, closing Tuesday at $1,107 with short sellers quietly reducing positions and analysts continuing to lift targets — a setup where the bear pressure…
Eli Lilly and Company has spent the week digesting the retatrutide data windfall, adding another 7.6% to close at $1,144.68 — and the Street is now visibly scrambling to keep its targets relevant. The analyst story has…
Eli Lilly and Company has given back a sliver of its remarkable May recovery, closing at $1,064 on June 2 — down 1.7% on the day but virtually unchanged on the week, as fresh safety questions around newly launched…
Eli Lilly and Company enters the final days of May having added 4.2% on the week, closing at $1,064.74 — its highest level since early in the year — with a fresh analyst target raise from BofA arriving the same day to…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LLY — free to start on ORTEX.
Sign up for free →Open LLY on ORTEX